Impetigo: Drug Development Pipeline Study, H1 2018
The most comprehensive pipeline review “Impetigo- Drug Development Pipeline Study” provides in-depth analysis and update information on Impetigo pipeline drugs. Current status of all the drugs in the Impetigo pipeline is provided in the research work.
The report provides detailed analysis of Impetigo pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Impetigo report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Impetigo industry.
Excerpts from- “Impetigo- Drug Development Pipeline Study”:
Impetigo pipeline comprises of 4 drugs under development as of February 2018. Of these, 2 drugs are in Phase 2 and 1 drug is in phase 2/3. Further, 1 drug is in Pre-Clinical Stage.
No drugs have been granted with Orphan drug designation by FDA/ EMA.
6 companies are developing the pipeline for Impetigo. Of this, all the companies are developing one drug each and the NovaBay Pharmaceuticals, Inc. therapeutic candidate is in Phase 2/3.
During December 2017, Xepi (ozenoxacin cream) of Ferrer Internacional S.A. has been approved. The drug is a DNA topoisomerase inhibitor.
Impetigo is a highly contagious bacterial skin infection that accounts for around one-tenth of all skin problems in the US. The condition is caused primarily by staphylococcal (staph) bacteria and occasionally with streptococcal (strep) bacteria. The bacteria enter the skin and causes impetigo.
Pediatric subjects between 2 and 6 years age are the most affected population. Symptoms typically include sores on face, arms and legs with reddish skin around the sores observed.
Scope:
The report provides detailed analysis of Impetigo pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Impetigo report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Impetigo industry.
Excerpts from- “Impetigo- Drug Development Pipeline Study”:
Impetigo pipeline comprises of 4 drugs under development as of February 2018. Of these, 2 drugs are in Phase 2 and 1 drug is in phase 2/3. Further, 1 drug is in Pre-Clinical Stage.
No drugs have been granted with Orphan drug designation by FDA/ EMA.
6 companies are developing the pipeline for Impetigo. Of this, all the companies are developing one drug each and the NovaBay Pharmaceuticals, Inc. therapeutic candidate is in Phase 2/3.
During December 2017, Xepi (ozenoxacin cream) of Ferrer Internacional S.A. has been approved. The drug is a DNA topoisomerase inhibitor.
Impetigo is a highly contagious bacterial skin infection that accounts for around one-tenth of all skin problems in the US. The condition is caused primarily by staphylococcal (staph) bacteria and occasionally with streptococcal (strep) bacteria. The bacteria enter the skin and causes impetigo.
Pediatric subjects between 2 and 6 years age are the most affected population. Symptoms typically include sores on face, arms and legs with reddish skin around the sores observed.
Scope:
- - All latest industry developments and their impact on projects and companies
- - Complete overview of global Impetigo therapy options and treatments
- - The pipeline study reviews drug details for Impetigo by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- - Mergers, Acquisitions, licensing, co-development and project acquisition news for Impetigo market
- - Impetigo drugs being developed in combination with other drugs are also detailed
- - Company wise drugs listed
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 IMPETIGO- COMPANY WISE PIPELINE ANALYSIS
3.1 DESTINY PHARMA LTD. PIPELINE, H1 2018
3.2 FOAMIX PHARMACEUTICALS LTD PIPELINE, H1 2018
3.3 LYTIX BIOPHARMA ASA PIPELINE, H1 2018
3.4 NOVABAY PHARMACEUTICALS, INC. PIPELINE, H1 2018
4 IMPETIGO PIPELINE DRUG SNAPSHOTS
4.1 XF 70 Drug Details
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Pre-clinical trials
4.1.5 Current Status
4.2 FMX 102 Drug Details
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Phase2 trial details
4.3 LTX-109 Drug Details
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Clinical Trial results
4.3.6 Pre-clinical study details
4.4 Auriclosene Drug Details
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Phase 2/3 trial details
4.4.5 Phase 2a/ 2b trial details
5 RECENT DEVELOPMENTS IN IMPETIGO PIPELINE
5.1 QUINOLONE APPROVED FOR THE TREATMENT OF IMPETIGO – December 2017
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 IMPETIGO- COMPANY WISE PIPELINE ANALYSIS
3.1 DESTINY PHARMA LTD. PIPELINE, H1 2018
3.2 FOAMIX PHARMACEUTICALS LTD PIPELINE, H1 2018
3.3 LYTIX BIOPHARMA ASA PIPELINE, H1 2018
3.4 NOVABAY PHARMACEUTICALS, INC. PIPELINE, H1 2018
4 IMPETIGO PIPELINE DRUG SNAPSHOTS
4.1 XF 70 Drug Details
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Pre-clinical trials
4.1.5 Current Status
4.2 FMX 102 Drug Details
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Phase2 trial details
4.3 LTX-109 Drug Details
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Clinical Trial results
4.3.6 Pre-clinical study details
4.4 Auriclosene Drug Details
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Phase 2/3 trial details
4.4.5 Phase 2a/ 2b trial details
5 RECENT DEVELOPMENTS IN IMPETIGO PIPELINE
5.1 QUINOLONE APPROVED FOR THE TREATMENT OF IMPETIGO – December 2017
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Impetigo Pipeline by Phase, H1- 2018
Figure 2: Impetigo Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Impetigo Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Impetigo Pipeline by Phase, H1- 2018
Figure 2: Impetigo Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Impetigo Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Impetigo Pipeline by Phase, H1- 2018
Table 2: Impetigo Pipeline by Companies, H1- 2018
Table 3: Impetigo Pipeline by Mechanism of Action, H1- 2018
Table 4: Destiny Pharma Ltd.- Impetigo Pipeline, H1- 2018
Table 5: Foamix Pharmaceuticals Ltd- Impetigo Pipeline, H1- 2018
Table 6: Lytix Biopharma ASA- Impetigo Pipeline, H1- 2018
Table 7: NovaBay Pharmaceuticals, Inc.- Impetigo Pipeline, H1- 2018
Table 1: Impetigo Pipeline by Phase, H1- 2018
Table 2: Impetigo Pipeline by Companies, H1- 2018
Table 3: Impetigo Pipeline by Mechanism of Action, H1- 2018
Table 4: Destiny Pharma Ltd.- Impetigo Pipeline, H1- 2018
Table 5: Foamix Pharmaceuticals Ltd- Impetigo Pipeline, H1- 2018
Table 6: Lytix Biopharma ASA- Impetigo Pipeline, H1- 2018
Table 7: NovaBay Pharmaceuticals, Inc.- Impetigo Pipeline, H1- 2018
